DHL, the German logistics giant, has signed an agreement to acquire Cryopdp, a U.S.-based company specializing in pharmaceutical logistics. The deal, reported by Reuters on Monday, is valued at hundreds of millions of euros, marking a significant investment in the expanding pharmaceutical supply chain sector.

Cryopdp is renowned for its expertise in temperature-sensitive pharmaceutical transportation, a critical component of the global healthcare industry. With the increasing demand for precise and secure pharmaceutical logistics, DHL’s acquisition aligns with its strategy to strengthen its position in this high-growth market.

While the exact financial details and timeline of the acquisition remain undisclosed, this move underscores DHL’s commitment to expanding its presence in the pharmaceutical logistics sector. The acquisition of Cryopdp is expected to enhance DHL’s capabilities in handling specialized pharmaceutical shipments, further solidifying its leadership in global logistics.